Biotek-snakken — Februar 2025
-
Saniona har en temmeligt stærk track record og en eksisterende flot pipeline. Der er tydeligtvis interesse derude, for at deltage; partner aftaler der kan sikre forretningen og en stabil kursudvikling over en årerække.. men den eksplodere ikke, da de ikke selv kører alt til ende. Personligt kan jeg bedst lide den model.. nu skal de ha hul på bylden.. første stik er taget hjem, næste burde være Tesofensine. Der som nævnt ikke er stor i hele casen, men vigtig shortterm, da der så kommer penge
-
Photocure indlæg fra Søren i debatten. https://proinvestor.com/boards/124588/
-
Det var så lidt.
-
Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study
https://storage.mfn.se/f49ff507-a199-47f0-bcd9-c763cd153496/ascelia-pharma-q4-2024-en.pdf
-
"A presentation for analysts, investors and media will be held today 7 February 2025 at 10:00am CET."
Ikke "idag 15 augusti kl. 10:00." som der står
i den svenske udgave
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind